Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Structure and functionality in flavivirus NS-proteins: perspectives for drug design.

Bollati M, Alvarez K, Assenberg R, Baronti C, Canard B, Cook S, Coutard B, Decroly E, de Lamballerie X, Gould EA, Grard G, Grimes JM, Hilgenfeld R, Jansson AM, Malet H, Mancini EJ, Mastrangelo E, Mattevi A, Milani M, Moureau G, Neyts J, Owens RJ, Ren J, Selisko B, Speroni S, Steuber H, Stuart DI, Unge T, Bolognesi M.

Antiviral Res. 2010 Aug;87(2):125-48. doi: 10.1016/j.antiviral.2009.11.009. Epub 2009 Nov 27. Review.

2.

A high-throughput screening assay for the identification of flavivirus NS5 capping enzyme GTP-binding inhibitors: implications for antiviral drug development.

Geiss BJ, Stahla-Beek HJ, Hannah AM, Gari HH, Henderson BR, Saeedi BJ, Keenan SM.

J Biomol Screen. 2011 Sep;16(8):852-61. doi: 10.1177/1087057111412183. Epub 2011 Jul 25.

3.

Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from Dengue virus as a target.

Lescar J, Luo D, Xu T, Sampath A, Lim SP, Canard B, Vasudevan SG.

Antiviral Res. 2008 Nov;80(2):94-101. doi: 10.1016/j.antiviral.2008.07.001. Epub 2008 Jul 30. Review.

PMID:
18674567
4.

The flavivirus NS2B-NS3 protease-helicase as a target for antiviral drug development.

Luo D, Vasudevan SG, Lescar J.

Antiviral Res. 2015 Jun;118:148-58. doi: 10.1016/j.antiviral.2015.03.014. Epub 2015 Apr 2. Review.

PMID:
25842996
5.

Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug.

Mastrangelo E, Pezzullo M, De Burghgraeve T, Kaptein S, Pastorino B, Dallmeier K, de Lamballerie X, Neyts J, Hanson AM, Frick DN, Bolognesi M, Milani M.

J Antimicrob Chemother. 2012 Aug;67(8):1884-94. doi: 10.1093/jac/dks147. Epub 2012 Apr 25.

6.

The flavivirus protease as a target for drug discovery.

Brecher M, Zhang J, Li H.

Virol Sin. 2013 Dec;28(6):326-36. doi: 10.1007/s12250-013-3390-x. Epub 2013 Nov 14. Review.

7.

Antiviral strategies to control calicivirus infections.

Rohayem J, Bergmann M, Gebhardt J, Gould E, Tucker P, Mattevi A, Unge T, Hilgenfeld R, Neyts J.

Antiviral Res. 2010 Aug;87(2):162-78. doi: 10.1016/j.antiviral.2010.05.002. Epub 2010 May 21. Review.

PMID:
20471996
8.

Identification of a novel antiviral inhibitor of the flavivirus guanylyltransferase enzyme.

Stahla-Beek HJ, April DG, Saeedi BJ, Hannah AM, Keenan SM, Geiss BJ.

J Virol. 2012 Aug;86(16):8730-9. doi: 10.1128/JVI.00384-12. Epub 2012 Jun 6.

9.

Genomics and structure/function studies of Rhabdoviridae proteins involved in replication and transcription.

Assenberg R, Delmas O, Morin B, Graham SC, De Lamballerie X, Laubert C, Coutard B, Grimes JM, Neyts J, Owens RJ, Brandt BW, Gorbalenya A, Tucker P, Stuart DI, Canard B, Bourhy H.

Antiviral Res. 2010 Aug;87(2):149-61. doi: 10.1016/j.antiviral.2010.02.322. Epub 2010 Feb 25. Review.

10.

The flavivirus polymerase as a target for drug discovery.

Malet H, Massé N, Selisko B, Romette JL, Alvarez K, Guillemot JC, Tolou H, Yap TL, Vasudevan S, Lescar J, Canard B.

Antiviral Res. 2008 Oct;80(1):23-35. doi: 10.1016/j.antiviral.2008.06.007. Epub 2008 Jul 9. Review.

PMID:
18611413
11.

Novel approaches to flavivirus drug discovery.

Botting C, Kuhn RJ.

Expert Opin Drug Discov. 2012 May;7(5):417-28. doi: 10.1517/17460441.2012.673579. Epub 2012 Mar 22. Review.

PMID:
22439769
12.

Nucleic acid-based inhibition of flavivirus infections.

Stein DA, Shi PY.

Front Biosci. 2008 Jan 1;13:1385-95. Review.

PMID:
17981637
13.

The Many Faces of the Flavivirus NS5 Protein in Antagonism of Type I Interferon Signaling.

Best SM.

J Virol. 2017 Jan 18;91(3). pii: e01970-16. doi: 10.1128/JVI.01970-16. Print 2017 Feb 1. Review.

14.

Flaviviral NS4b, chameleon and jack-in-the-box roles in viral replication and pathogenesis, and a molecular target for antiviral intervention.

Zmurko J, Neyts J, Dallmeier K.

Rev Med Virol. 2015 Jul;25(4):205-23. doi: 10.1002/rmv.1835. Epub 2015 Apr 1. Review.

15.

Molecular targets for flavivirus drug discovery.

Sampath A, Padmanabhan R.

Antiviral Res. 2009 Jan;81(1):6-15. doi: 10.1016/j.antiviral.2008.08.004. Epub 2008 Sep 15. Review.

16.

Novel Broad Spectrum Inhibitors Targeting the Flavivirus Methyltransferase.

Brecher M, Chen H, Liu B, Banavali NK, Jones SA, Zhang J, Li Z, Kramer LD, Li H.

PLoS One. 2015 Jun 22;10(6):e0130062. doi: 10.1371/journal.pone.0130062. eCollection 2015.

17.

Targeting dengue virus NS4B protein for drug discovery.

Xie X, Zou J, Wang QY, Shi PY.

Antiviral Res. 2015 Jun;118:39-45. doi: 10.1016/j.antiviral.2015.03.007. Epub 2015 Mar 19. Review.

PMID:
25796970
18.

Flavivirus NS3 and NS5 proteins interaction network: a high-throughput yeast two-hybrid screen.

Le Breton M, Meyniel-Schicklin L, Deloire A, Coutard B, Canard B, de Lamballerie X, Andre P, Rabourdin-Combe C, Lotteau V, Davoust N.

BMC Microbiol. 2011 Oct 20;11:234. doi: 10.1186/1471-2180-11-234.

19.

Drug design for flavivirus proteases: what are we missing?

Poulsen A, Kang C, Keller TH.

Curr Pharm Des. 2014;20(21):3422-7. Review.

PMID:
24001226
20.

Flavivirus NS1: a multifaceted enigmatic viral protein.

Rastogi M, Sharma N, Singh SK.

Virol J. 2016 Jul 29;13:131. doi: 10.1186/s12985-016-0590-7. Review.

Supplemental Content

Support Center